+1 (514) 956-2525

2300 Alfred Nobel, Suite 230, Montreal, QC, H4S 2A4, Canada



SoundBite Medical Solutions Named Company of the Year 2018 by Anges Québec

MONTREAL – June 22nd, 2018 – SoundBite Medical Solutions Inc. (SBMS) has been selected as Company of the Year by Anges Quebec. “We are very honored to be named Company of the Year 2018 by Anges Québec,” said Francis Bellido, SoundBite President & CEO. “This award highlights the exciting growth we’ve achieved as a key player in the field of CTOs and vessel prep and recognizes the excellent work of our greatest asset, our employees. I also want to thank Anges Quebec members for their indefectible support since the beginning of the company.” The trophy was presented to SBMS during a ceremony in Saint-Jean-sur-Richelieu, last Thursday. About SoundBite Medical Solutions SoundBite is a privately-held medical device company developing products in the field of vessel preparation for the management and...


SoundBite Medical Solutions Completes $25 million Series A Financing

MONTREAL - June 12th, 2018 – SoundBite Medical Solutions Inc. (SBMS) today announced the closing of a $5.2 million second and final tranche of Series A financing, bringing the total proceeds raised in the Series A financing to $25 million. In April 2018, SBMS closed a first tranche of Series A financing, led by Fidelity Investments Canada ULC. The second tranche included existing shareholders as well as new investors. SBMS intends to use the new capital to further advance its clinical and product development programs over the next 30 months. This includes the ongoing pivotal clinical programs for the SoundBite™ Active Wire in the coronary and peripheral indications, as well as a First-In-Man clinical trial for the SoundBite™ Active Microcatheter. SoundBite™ Active Wire received...


SoundBite Announces Successful Series A Financing and the Appointment of a New CEO

MONTREAL - April 10th, 2018 – SoundBite Medical Solutions Inc. (SBMS) today announces the closing of a $19.9 million Series A financing, with a possibility of raising more funds in a second tranche later in the quarter. This round of financing included participation by new and existing Canadian and international investors, including Fidelity Investments Canada ULC. These new cash proceeds will be used to prepare for a strategic commercial launch in Europe after recently obtaining CE Mark approval. In addition, it will allow the company to complete a First-In-Man clinical trial for the SoundBite™ Active Microcatheter and to accelerate its pivotal clinical development plan in order to achieve FDA approval for the peripheral and coronary chronic total occlusion (CTO) indications within the next 30 months. “The...


SoundBite announces CE Mark Approval for SoundBite™ Crossing System – Peripheral

MONTREAL March 27th, 2018 – SoundBite Medical Solutions Inc. (SBMS) today announces it has received CE Marking for the SoundBite™ Crossing System, a unique and novel first-in-class wire-based technology that is intended for the treatment of peripheral chronic total occlusions (CTOs) in a simpler and clinically efficient method. “We are pleased that our notified body verified that we have objectively demonstrated the safety and efficacy in Europe of our CTO crossing technology through bench and clinical studies,” said Marc-André Côté, Director, Regulatory Affairs, “and that we were able to demonstrate the effective tracking of our activities in an ISO 13485-certified quality management system,” added Abderrahim Benrabah, Vice-President, Quality Engineering. CE Marking indicates that the product complies with the Essential Requirements of the 93/42/EEC Directive and is authorized...


SoundBite is Named One of 2017’s Best Scientific Discoveries by Québec Science Magazine

MONTREAL January 30th, 2018 – SoundBite Medical Solutions Inc. (SBMS), has been selected as a finalist in the 2017 “Discovery of the Year” contest by Québec Science Magazine. The discovery has been named top 10 within Québec out of the 124 applications it received. SoundBite was selected on the basis of an article describing its first-in-human case: “Novel crossing system for chronic total occlusion recanalization: First-in-man experience with the SoundBite crossing system, Benko et al., Journal of Invasive Cardiology 29(2):E17-E20” and the award of a patent covering its core technology: “Mechanical wave generator and method thereof, Brouillette et al., U.S. Patent 9,833,373.” Every fall for the last 25 years, Québec Science has been selecting the 10 most notable Québec discoveries of the year through a...


SoundBite Announces Successful Completion of First-In-Man Clinical Study for Peripheral Chronic Total Occlusions (CTO) Crossing Procedures

MONTREAL – December 20th, 2017 – SoundBite Medical Solutions Inc. (SBMS) announced today that its First-In-Human prospective, single-arm and multi-center clinical trial using SoundBite’s shock wave energy system has been successfully completed. Thirty-seven (37) patients suffering from chronic total occlusion (CTO) were treated in three sites (Montréal, Sherbrooke and Graz (Austria)) with a clinical success rate of 92% and no serious adverse events. Dr. Andrew Benko, Chief of Angiography and Endovascular Therapy at the Sherbrooke University Hospital (CHUS) and Principal Investigator of the clinical trial, stated, “This technology fulfills an important need in the field of CTO intervention as it can convert failed procedures into successes, giving the patient relief from ischemic pain and even saving their limb”. In total, 41 lesions from 37 patients were treated...


SoundBite announces new CEO

MONTREAL, July 28 2017 – SoundBite Medical Solutions Inc. (SBMS), a Montreal-based cardiovascular medical technology company, is pleased to announce that Martin Brouillette, Co-Founder and Chief Technology Officer, has been named Chief Executive Officer. Martin is the one of the inventors of Soundbite’s proprietary technology and has been instrumental in all aspects of the company's development to date including the recent First-in-Human trial. Martin has also spearheaded pre-clinical developments, driven the widening of the company’s products portfolio and was a key player in Soundbite’s very successful $15M Seed Round financing. Martin will lead SoundBite to maximize its potential in developing not only treatments for interventional vascular care but also in the much larger field of vessel preparation, leveraging his strong technical expertise and leadership. He succeeds...


SoundBite Announces the Hiring of Abder Benrabah to the position of Vice-President, Quality Engineering and Assurance

MONTREAL, March 1st, 2017 – SoundBite Medical Solutions Inc. (SBMS Inc.), a Montreal-based cardiovascular (CV) medical technology company, is pleased to announce its recent hire of Abder Benrabah, an industry Quality Assurance (QA) and Regulatory Affairs (RA) leader in medical devices. Mr. Benrabah will join the SBMS team as Vice-President Quality Engineering and Assurance, to lead the quality function of SoundBite’s shockwave technology in the exciting and challenging arena of chronic total occlusions (CTOs) of the cardiovascular system. Mr. Benrabah brings over twenty-six years of leadership experience in various fields, including medical devices. He has held various management positions in QA, RA and Continuous Improvement at CryoCath Technologies, Biorthex Inc. & PerkinElmer BioSignal. Abder joins SBMS Inc. from Smith & Nephew Inc. where he...


SoundBite Initiates Human Clinical Studies for Peripheral CTO Crossing Procedures

MONTREAL – December 6th, 2016 – SoundBite Medical Solutions Inc. (SBMS) announced today that it has performed its First-In-Human (FIH) procedure using shockwave energy to successfully and safely cross a chronic total occlusion (CTO). The 72-year-old male patient had bilateral superficial femoral artery occlusions (both over 20 cm in length) in the legs, leading to incapacitating claudication and unfavorable quality of life. Dr. Andrew Benko, performed the minimally invasive procedure using a .018” guidewire (ShockWire™) that delivered high energy shockwaves into the patient’s arteries to completely cross both occlusions including several calcified nodules and re-establish blood flow. In up to 30% of cases, these type of occlusions could be difficult and sometimes impossible to cross, resulting in a need for surgical intervention and potentially amputation. ...


SoundBite Announces a New Financing

Montreal, Canada - October 31st 2016 - SoundBite Medical Solutions Inc. (SBMS), a Montreal and Sherbrooke-based cardiovascular medical technology company, announced today the third closing of the seed equity round for $5 million. The financing was co-led by new Canadian investors Accel-Rx Health Sciences Accelerator, BDC Capital and the Bertrand group. “This third and final closing of our Seed Equity Round is further evidence of the strong interest SoundBite’s technology and business model have generated in the financial community” says Francis Bellido, CFO of SBMS Inc. This new financing brings the total cash proceeds from all the financings to $14 million. These funds will be used to accelerate our clinical development plan for our pivotal trial and prepare for a...